Final height in Turner syndrome patients treated with growth hormone.
The first treatment trials on patients presenting with Turner syndrome were successful in accelerating growth velocity. It is therefore essential to know the final height of the patients who were treated in order to ascertain whether or not growth hormone treatment increases final height. We are reporting on a group of 117 patients with Turner syndrome whose growth hormone treatment was initiated in 1986. The mean growth hormone dose was 0.74 IU/kg/week for an average period of 4 years. At the start of treatment, the patients' chronological age was 129/12 years, height -3.8 +/- 1.0 standard deviation scores (SDS) and bone age 10.5 +/- 2.1 years. Mean final height was 147.7 +/- 5.6 cm, i.e. a gain of 1.5 SDS. We noted no significant difference due to the type of chromosomal abnormality, nor to oxandrolone or estrogen-associated treatment. A significant correlation was found between final height, mean parental height, the duration of the treatment, height SDS at the start of treatment and growth hormone peak during pharmacological stimulation tests. However, there was no correlation between growth hormone dosage, chronological age and bone age at the start of treatment. These results show that the growth hormone treatment improves the final heights of patients with Turner syndrome.
Service d'Endocrinologie infantile, CHU Purpan, Toulouse, France.
P
P
Rochiccioli
J
J
Battin
A M
AM
Bertrand
M
M
Bost
S
S
Cabrol
Y
Y
le Bouc
J L
JL
Chaussain
P
P
Chatelain
M
M
Colle
P
P
Czernichow
D000365:Age Determination by Skeleton; D045930:Anabolic Agents / Q000627:therapeutic use; D001827:Body Height / Q000187:drug effects* / Q000502:physiology*; D002648:Child; D002869:Chromosome Aberrations / Q000503:physiopathology; D025063:Chromosome Disorders; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D005602:France; D013006:Growth Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D010074:Oxandrolone / Q000627:therapeutic use; D012044:Regression Analysis; D014424:Turner Syndrome / Q000188:drug therapy* / Q000503:physiopathology*
D045930:Anabolic Agents; D004967:Estrogens; D010074:Oxandrolone; D013006:Growth Hormone